The centrally restricted diffusion sign on MRI for assessment of radiation necrosis in metastases treated with stereotactic radiosurgery.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 22 09 2021
accepted: 16 10 2021
pubmed: 25 10 2021
medline: 3 3 2022
entrez: 24 10 2021
Statut: ppublish

Résumé

Differentiation of radiation necrosis from tumor progression in brain metastases treated with stereotactic radiosurgery (SRS) is challenging. For this, we assessed the performance of the centrally restricted diffusion sign. Patients with brain metastases treated with SRS who underwent a subsequent intervention (biopsy/resection) for a ring-enhancing lesion on preoperative MRI between 2000 and 2020 were included. Excluded were lesions containing increased susceptibility limiting assessment of DWI. Two neuroradiologists classified the location of the diffusion restriction with respect to the post-contrast T1 images as centrally within the ring-enhancement (the centrally restricted diffusion sign), peripherally correlating to the rim of contrast enhancement, both locations, or none. Measures of diagnostic accuracy and 95% CI were calculated for the centrally restricted diffusion sign. Cohen's kappa was calculated to identify the interobserver agreement. Fifty-nine patients (36 female; mean age 59, range 40 to 80) were included, 36 with tumor progression and 23 with radiation necrosis based on histopathology. Primary tumors included 34 lung, 12 breast, 5 melanoma, 3 colorectal, 2 esophagus, 1 head and neck, 1 endometrium, and 1 thyroid. The centrally restricted diffusion sign was seen in 19/23 radiation necrosis cases (sensitivity 83% (95% CI 63 to 93%), specificity 64% (95% CI 48 to 78%), PPV 59% (95% CI 42 to 74%), NPV 85% (95% CI 68 to 94%)) and 13/36 tumor progression cases (difference p < 0.001). Interobserver agreement was substantial, at 0.61 (95% CI 0.45 to 70.8). We found a low probability of radiation necrosis in the absence of the centrally restricted diffusion sign.

Identifiants

pubmed: 34689307
doi: 10.1007/s11060-021-03879-4
pii: 10.1007/s11060-021-03879-4
pmc: PMC8651583
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

325-333

Informations de copyright

© 2021. The Author(s).

Références

Neurosurg Rev. 2014 Apr;37(2):193-201; discussion 201
pubmed: 24233257
AJR Am J Roentgenol. 2018 Jul;211(1):168-175
pubmed: 29708785
Neoplasia. 2009 Feb;11(2):102-25
pubmed: 19186405
AJNR Am J Neuroradiol. 2000 Aug;21(7):1190-4
pubmed: 10954267
J Nucl Med. 2012 Sep;53(9):1367-74
pubmed: 22872742
Cancer Treat Res. 2007;136:1-21
pubmed: 18078262
AJNR Am J Neuroradiol. 2011 Nov-Dec;32(10):1885-92
pubmed: 21920854
AJNR Am J Neuroradiol. 2018 Feb;39(2):260-264
pubmed: 29217742
AJNR Am J Neuroradiol. 2020 Nov;41(11):2049-2054
pubmed: 33060101
Lancet Oncol. 2008 May;9(5):453-61
pubmed: 18452856
Neuro Oncol. 2014 Jan;16(1):131-9
pubmed: 24327584
J Neurooncol. 2010 Aug;99(1):81-8
pubmed: 20058049
Mol Interv. 2004 Oct;4(5):273-84
pubmed: 15471910
J Neurooncol. 2012 Mar;107(1):51-60
pubmed: 21948114
Neurosurgery. 2002 Oct;51(4):912-9; discussion 919-20
pubmed: 12234397
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1455-60
pubmed: 15956515
Brain Tumor Res Treat. 2016 Oct;4(2):116-123
pubmed: 27867922
Cancer. 2012 May 1;118(9):2486-93
pubmed: 21887683
Int J Mol Sci. 2014 Jul 03;15(7):11832-46
pubmed: 24995696
J Neurooncol. 2005 Oct;75(1):5-14
pubmed: 16215811
Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1464-70
pubmed: 15248032
Radiology. 2000 Nov;217(2):331-45
pubmed: 11058626
Lancet Oncol. 2014 Apr;15(4):387-95
pubmed: 24621620
Eur Radiol. 2013 Mar;23(3):879-86
pubmed: 22903642
AJNR Am J Neuroradiol. 2014 Nov-Dec;35(11):2082-90
pubmed: 24970548
Eur J Radiol Open. 2017 Jul 10;4:84-88
pubmed: 28725661
Nat Clin Pract Oncol. 2008 Apr;5(4):220-33
pubmed: 18301415
BMC Cancer. 2017 Nov 6;17(1):713
pubmed: 29110648
AJNR Am J Neuroradiol. 2011 Dec;32(11):1978-85
pubmed: 21393407
AJNR Am J Neuroradiol. 2004 Feb;25(2):201-9
pubmed: 14970018
Surg Neurol. 2008 Jan;69(1):62-8; discussion 68
pubmed: 18054618
AJNR Am J Neuroradiol. 2009 Feb;30(2):367-72
pubmed: 19022867
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
Neuro Oncol. 2017 Apr 1;19(suppl_2):ii2-ii15
pubmed: 28380635
Brain Tumor Pathol. 2006 Apr;23(1):19-27
pubmed: 18095115
J Neurooncol. 2017 Sep;134(2):433-441
pubmed: 28674974
Neurosurgery. 2010 Jan;66(1):208-17
pubmed: 20023552
Front Oncol. 2018 Sep 28;8:395
pubmed: 30324090
Neuro Oncol. 2013 May;15(5):515-34
pubmed: 23325863
J Neurol. 2009 Jun;256(6):878-87
pubmed: 19274425
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571

Auteurs

Nicolin Hainc (N)

Department of Medical Imaging, University of Toronto, Toronto, Canada. Nicolin.hainc@usz.ch.
Department of Neuroradiology, Clinical Neuroscience Center, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland. Nicolin.hainc@usz.ch.

Noor Alsafwani (N)

Laboratory Medicine Program, University Health Network, Toronto, Canada.
Department of Pathology, College of Medicine, Imam Abdulrahman Bin Faisal University (IAU), Dammam, Saudi Arabia.

Andrew Gao (A)

Laboratory Medicine Program, University Health Network, Toronto, Canada.

Philip J O'Halloran (PJ)

Neurosurgery, University Health Network, Toronto, Canada.

Paul Kongkham (P)

Neurosurgery, University Health Network, Toronto, Canada.

Gelareh Zadeh (G)

Neurosurgery, University Health Network, Toronto, Canada.

Enrique Gutierrez (E)

Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Canada.

David Shultz (D)

Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Canada.

Timo Krings (T)

Department of Medical Imaging, University of Toronto, Toronto, Canada.
Joint Department of Medical Imaging, University Health Network, Toronto, Canada.

Paula Alcaide-Leon (P)

Department of Medical Imaging, University of Toronto, Toronto, Canada.
Joint Department of Medical Imaging, University Health Network, Toronto, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH